According to a recent LinkedIn post from M Ventures, portfolio company STORM Therapeutics has closed a $56 million Series C financing round. The post highlights that the capital is intended to support the company’s focus on targeting RNA modifications to reprogram cells and develop cancer therapies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post further notes that the funding will accelerate development of STC-15, described as a first-in-class, oral small-molecule METTL3 inhibitor. It also indicates that the first patient has been dosed in a Phase 2 monotherapy study in selected sarcoma indications.
For investors, the post suggests meaningful de-risking of STORM Therapeutics’ lead asset through advancement into mid-stage trials, alongside strengthened balance-sheet visibility from the new capital. Progress in sarcoma with a potential path to accelerated regulatory review could, if successful, expand the company’s addressable oncology market and enhance the value of M Ventures’ stake.
The financing may also imply continued investor appetite for RNA-modification platforms despite broader volatility in biotech funding cycles. If STC-15 generates positive Phase 2 data, it could position STORM as a differentiated player in precision oncology and create optionality for future partnering, follow-on financing, or exit scenarios that may benefit M Ventures’ overall portfolio returns.